Core Viewpoint - Longfor Group demonstrates a steady operational performance with ongoing transformation effects, as evidenced by its January 2026 sales data and overall financial results [1][3]. Group 1: Operational Performance - In January 2026, Longfor Group achieved a contract sales amount of 2.45 billion yuan, with a sales area of 300,000 square meters [1]. - The revenue for January 2026 reached approximately 2.27 billion yuan, with a year-on-year growth of 5.1% [1]. - For the full year of 2025, Longfor Group reported operational revenue of approximately 26.77 billion yuan, with a tax-inclusive amount of about 28.54 billion yuan, reflecting a 5.0% year-on-year increase [2]. Group 2: Land Acquisition and Development - In January 2026, Longfor Group added two new land reserves in Qingdao and Wuxi, with a total construction area of 142,947 square meters and an equity land price of 865 million yuan [2]. - The land acquisition strategy has shifted towards quality over quantity, with a land acquisition amount of approximately 3.6 billion yuan in 2025, representing a land acquisition intensity of about 6% [3]. Group 3: Market Position and Future Outlook - Huatai Securities indicates that Longfor Group's value is underestimated, particularly in commercial real estate and service business growth potential [3]. - The company has maintained a disciplined financial approach, which positions it favorably within the industry, especially as the market begins to recover [4]. - Recent reports from various securities firms suggest that the most challenging period for the real estate industry may be over, with quality developers like Longfor Group expected to lead the recovery [5].

Core Viewpoint - Pacific Shipping (02343) has seen a significant increase in stock price, rising over 4% following the commencement of operations at the Simandou iron ore project in Guinea, which is expected to boost dry bulk shipping demand [1] Group 1: Company Performance - Pacific Shipping's stock price rose by 4.43%, reaching HKD 3.3, with a trading volume of HKD 49.38 million [1] - The company is positioned as a leader in the small bulk shipping sector, with analysts suggesting that the industry is approaching a bottoming point, indicating potential for significant earnings elasticity [1] Group 2: Industry Outlook - The commencement of operations at the Simandou iron ore project and the continuous growth in bauxite exports are anticipated to extend the shipping distances for dry bulk, leading to increased demand for shipping capacity [1] - The resolution of conflicts such as the Russia-Ukraine and Israel-Palestine situations could further enhance dry bulk transportation demand due to post-war reconstruction efforts [1] - Analysts from Huachuang Securities predict that the interest rate reduction cycle may stimulate physical demand growth, benefiting the shipping industry [1] - The Simandou project is expected to provide substantial turnover increments for the large vessel market, which may positively influence the small vessel market due to the interconnected nature of these markets [1]

摩根士丹利发表研报，更新对中国酒店及休闲公司模型的预测，以反映该行最新的行业展望及各公司相 对的营运表现。该行的偏好顺序为华住集团、亚朵、首旅酒店、锦江酒店及中青旅。随着中国酒店每间 可售房收入已结束连续两年的下降趋势，且行业基本面转为支持性，该行看到一个从下行周期环境转向 复苏阶段的明确转变。大摩将香港/内地休闲及住宿行业观点上调至"吸引"，将2026年至2027年的盈利 预测平均上调约10%。大摩将华住目标价由47美元上调至65美元，亚朵目标价由40美元上调至45美元， 评级为"增持"。 ...

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **pharmaceutical industry**, particularly the **CDMO (Contract Development and Manufacturing Organization)** sector, highlighting key players like **Lonza** and **Samsung Biologics** [1][2]. Core Insights and Arguments - **Lonza's Financial Performance**: - For the year 2025, Lonza reported sales of **65.31 billion Swiss Francs**, with a constant exchange rate (CER) year-over-year growth of **21.7%**. - The core EBITDA margin improved by **1.4 percentage points** to **31.6%**, exceeding the revised annual expectations [1]. - The company maintains an optimistic outlook for 2026, projecting a **11-12%** CER year-over-year growth in CDMO sales and an EBITDA margin surpassing **32%** [1]. - **Upcoming Financial Disclosures**: - February will see a concentrated disclosure period for several leading CXO companies, which will provide insights into revenue, profits, orders, and capacity planning, along with 2026 operational guidance [2]. - **Strategic Collaborations**: - On January 30, **Shijiazhuang Pharmaceutical Group** announced a strategic R&D collaboration with **AstraZeneca** to develop innovative long-acting peptide drugs using its proprietary sustained-release drug delivery technology and AI drug discovery platform [2]. - **Growth Projections for CXO Companies**: - Given the order-to-performance conversion cycle, it is anticipated that CXO companies will continue to experience rapid growth over the next **1-2 years** [2]. Additional Important Content - **Medical Devices and Biologics**: - Roche reported positive topline results from the **CT388-103 Phase II clinical trial**, suggesting continued monitoring of subsequent R&D progress [3]. - **Medical Services and Consumer Healthcare**: - **Gushengtang** plans to issue convertible bonds totaling **$110 million** (approximately **860 million Hong Kong Dollars**) [3]. - **Synergistic Opportunities**: - There is potential for deep collaboration in business synergy and resource integration, which could yield significant synergistic effects [4]. - **Chinese Herbal Medicine**: - Some companies are expected to achieve good results in inventory reduction, and with a low base, the operational trend for 2026 is anticipated to improve, suggesting potential turnaround opportunities for certain companies [4]. - **Overall Industry Recovery**: - The combination of overseas CXO annual reports and 2026 performance guidance, along with domestic CXO companies' 2025 performance forecasts, indicates a clear recovery rhythm and upward trend in the industry, presenting strong investment value and suggesting active positioning [4].

Group 1 - The company expects to turn a profit in the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors [1][3] - The main reasons for the performance changes include stable revenue growth due to industry recovery, with specific impacts from the FCBGA packaging substrate business and the high-layer PCB business [3] Group 2 - The FCBGA packaging substrate business has not yet achieved mass production, resulting in a financial drag with an annual expense of approximately 660 million yuan, although sample order quantities have significantly increased year-on-year [3] - The high-layer PCB business incurred a loss of about 100 million yuan for the year, but quarterly losses have been narrowing, nearing breakeven in the fourth quarter [3] - Other financial impacts include interest expenses from convertible bonds of approximately 17 million yuan, a fair value loss of about 38 million yuan from equity redemption rights, and an increase in income tax expenses of about 36 million yuan due to high-tech enterprise certification [4] Group 3 - The total impact on the company's net profit attributable to shareholders is approximately 100 million yuan [5] - The company has not identified any significant uncertainties affecting the accuracy of the performance forecast as of the announcement date [6]

大摩又指，集团管理层对行业前景保持乐观，而近期的一次会议上，管理层提到中国CRO行业似乎正 处于复苏态势。 摩根士丹利表示，强劲的盈利增长主要归因于泰格医药资产的大幅重估，以及2024年相对较低的基数。 尽管受订单取消及收款困难影响，集团经常性收益表现疲软，但公司新订单增长依然强劲。扣除取消订 单后的新增在手订单净额介于95亿元至105亿元，同比增长13%至25%。 智通财经APP获悉，摩根士丹利发布研报称，泰格医药(03347)公布2025年初步业绩，营收介乎为66.6亿 元至76.8亿元人民币(下同)，同比增长1%至16%。该范围较摩根士丹利预估为低2%至高12%。净利润介 乎8.3亿元至12.3亿元，同比增长105%至增长204%。予泰格医药(300347.SZ)A股目标价81元，评级"增 持"。 ...

Core Viewpoint - Mingyang Circuit (300739.SZ) expects a net profit attributable to shareholders of 78 million to 95 million yuan for 2025, representing a year-on-year growth of 585.19% to 734.52% [1] Group 1: Business Focus and Strategy - The company continues to focus on its core business and actively seizes opportunities from industry recovery [1] - It is deepening market development and strengthening relationships with key customers [1] - The company is increasing research and investment in high-value areas such as high-speed products and semiconductor test boards, promoting product structure optimization [1] Group 2: Operational Efficiency - The company is fully advancing lean production and quality improvement initiatives [1] - These efforts are expected to lead to significant growth in annual performance [1]

南财智讯1月27日电，深科达发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 2000.00万元—2900.00万元，预计同比扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益 的净利润为1700.00万元—2450.00万元。本期业绩变化的主要原因：1、报告期内，全球半导体行业及消 费电子细分领域（智能穿戴、电子纸、OLED面板扩产）需求呈稳步回暖态势。公司紧抓行业复苏的市 场机遇，深化与优质客户的长期战略合作，同时在研发、生产、销售及经营全流程推进精益管理，推动 公司毛利率、净利率水平较上年同期实现显著改善。 ...

深科达公告，预计2025年年度实现归属于母公司所有者的净利润2000万元到2900万元，与上年同期相 比，将实现扭亏为盈。预计归属于母公司所有者扣除非经常性损益后的净利润1700万元到2450万元。上 年同期归属于母公司所有者的净利润为-1.06亿元。报告期内，全球半导体行业及消费电子细分领域需 求呈稳步回暖态势。公司紧抓行业复苏的市场机遇，深化与优质客户的长期战略合作，同时在研发、生 产、销售及经营全流程推进精益管理，推动公司毛利率、净利率水平较上年同期实现显著改善。 ...

Core Viewpoint - The liquor industry is expected to experience a peak marketing season during the upcoming Spring Festival, with distributors learning from leading companies' multi-dimensional reforms in channels and products [1] Group 1: Industry Trends - The industry is likely to refocus on market cultivation and consumer education under new reforms and directions, promoting sales and alleviating burdens on distributors [1] - Considering various factors such as stable sales, an additional day off during the 2026 Spring Festival, and consumption scenarios, actual sales of liquor during the 2026 Spring Festival are expected to remain stable, indicating no need for excessive pessimism [1] Group 2: Future Outlook - A gradual recovery trend is anticipated, with a positive outlook on bottom-fishing opportunities in the liquor industry [1] - The beer industry is expected to experience a mild recovery from a bottom position in 2026, with a recommendation to focus on industry leaders that possess strong channel control and brand premium capabilities [1]